Ingevity Q1: adjusted EBITDA $91.3M (+23%); sales $284M (-17%); FY guidance revised

Ingevity Corp

2025-Q1 EPS reported $0.56 revenue$284,000,000

Net sales $284.0M, down 17% YoY, due to Performance Chemicals repositioning and exit of lower-margin markets.
Net income $20.5M, diluted EPS $0.56; adjusted earnings $36.4M, adjusted EPS $0.99.
Adjusted EBITDA $91.3M (+23% YoY); margin improved to 32.1%.
Revised FY2025 guidance: sales $1.25B-$1.40B, adjusted EBITDA $380M-$415M, citing tariff uncertainty and auto production declines.
Operating cash flow $25.4M; free cash flow $15.4M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.